Table 2.
Outcomes in the studies included in the meta-analysis
| First Author [Reference No.] |
Outcomes, n° (%) of patients in Peg-IFN α-2a/α-2b group |
|
|||||
|---|---|---|---|---|---|---|---|
| RVR | EVR | ETR | SVR | Discontinuation of therapy for adverse events in patients with genotype 1 all genotypes | Peg-IFN reduction for adverse events in patients with all genotypes | ||
| Yenice [16] # |
|
|
28(75.7)/27(73) |
18(48.6)/13(35.1) |
3 (7.5)/3 (7.5) |
3 (7.5)/3 (7.5) |
|
| Di Bisceglie [17] § |
14(7.4)/22(11.5) |
74(39.1)/84(43.9) |
|
|
|
|
|
| Escudero [18] † |
15(25.4)/10(17.2) |
33(55.9)/29(50) |
12(20.3)/7(12.1) |
30(50.8)/27(46.6) |
|
12(13.1)/10(10.8) |
8(8.7)/7(7.6) |
| McHutchison [19] $ |
123(11.9)/116(11.4) |
466(45)/407(39.9) |
667(64.4)/542(53.2) |
423(40.9)/406(39.8) |
135(13)/129(12.6) |
135(13)/129(12.6) |
264(25.5)/254(24.9) |
| Ascione [20] § |
|
|
|
51(54.8)/37(39.8) |
3 (3.2)/13 (14) |
4(2.5)/22(13.7) |
|
| Lee [21] ^ |
|
16(76.2)/12(75) |
16(76.2)/13(81.3) |
8(38)/10(62.5) |
|
8(10.1)/5(10.6) |
|
| Rumi [22] ç | 34(37)/26(30) | 60(66)/40(46) | 59(65)/38(44) | 44(48)/28(32) | 16(7.5)/17(7.7) | 22(10.3)/14(6.3) | |
Dosage of ribavirin
# 40–64 kg of weight: 800 mg/day; 65–85 kg: 1,000 mg/day; >85 kg: 1,200 mg/day.
§ <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day.
† ≤65 kg of weight: 800 mg/day; 65–75 kg: 1,000 mg/day; >75 kg: 1,200 mg/day.
$ In the Peg-IFN α-2b arm: 40–65 kg of weight: 800 mg/day; >65-85 kg: 1,000 mg/day; >85-105 kg: 1,200 mg/day; >105-125 kg: 1,400 mg/day. In the Peg-IFN α-2a arm: <75 kg: 1,000 mg/day; ≥75 kg: 1,200 mg/day.
^ In the Peg-IFN α-2a arm: <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day. In the Peg-IFN α-2b arm: <65 kg: 800 mg/day; 65–85 kg: 1,000 mg; >85 kg: 1,200 mg.
ç <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day.